For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Liraglutide - Diabetes Mellitus
PAD Profile : Liraglutide - Diabetes Mellitus
Traffic Light Status
Status 1 of 3.
- Not Specified
Status 2 of 3.
- Not Specified
Status 3 of 3.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
Liraglutide is 1st-line for patients who wish to have a daily GLP-1 injection.
Dulaglutide continues to be the preferred GLP-1 where weekly injection is indicated.
Semaglutide is an alternative option for weekly injection.
Lixisenatide is no longer a preferred treatment but remains an option.
Treatment with GLP-1s should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance
A PREFERRED GLP-1 RECEPTOR AGONIST: Widely used, dose adjustment not required in severe renal impairment and has randomised controlled trial data to show improved cardiovascular outcomes Treatment should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance